EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Resveratrol differentially affects MMP‐9 release from neurons and glia; implications for therapeutic efficacy

Matthew Amontree, Matthew Nelson, Lara Stefansson, Daniel Pak, Kathleen Maguire-Zeiss, R Scott Turner, Katherine Conant iD

Journal of Neurochemistry · 2024-09 · 168 (9) · 1895-1908

DOI: 10.1111/jnc.16031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurochemistry, 2024-01. Verfasst von Matthew Amontree und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Georgetown University Medical Center, Washington, District of Columbia, USA. Hauptthemen laut MEDLINE: Resveratrol, Matrix Metalloproteinase 9, Neurons, Neuroglia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NIA NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resveratrol, a naturally occurring polyphenol that activates sirtuin 1 (SIRT1), has been shown to reduce overall levels of matrix metalloprotease‐9 (MMP‐9) in cerebrospinal fluid (CSF) samples from patients with Alzheimer's dementia (AD). Depending on the site of release, however, MMP‐9 has the potential to improve or impair cognition. In particular, its release from microglia or pericytes proximal to the blood brain barrier can damage the basement membrane, while neuronal activity‐dependent release of this protease from glutamatergic neurons can instead promote dendritic spine expansion and long‐term potentiation of synaptic plasticity. In the present study, we test the hypothesis that resveratrol reduces overall MMP‐9 levels in CSF samples from patients with APOE4, an allele associated with increased glial inflammation. We also examine the possibility that resveratrol reduces inflammation‐associated MMP release from cultured glia but spares neuronal activity‐dependent release from cultured cortical neurons. We observe that resveratrol decreases overall levels of MMP‐2 and MMP‐9 in CSF samples from AD patients. Resveratrol also reduces CSF levels of tissue inhibitor of metalloproteinases‐1 (TIMP‐1), glial‐derived protein that restricts long‐term potentiation of synaptic transmission, in individuals homozygous for APOE4. Consistent with these results, we observe that resveratrol reduces basal and lipopolysaccharide (LPS)‐stimulated MMP and TIMP‐1 release from cultured microglia and astrocytes. In contrast, however, resveratrol does not inhibit release of MMP‐9 from cortical neurons. Overall, these results are consistent with the possibility that while resveratrol reduces potentially maladaptive MMP and TIMP‐1 release from activated glia, neuroplasticity‐promoting MMP release from neurons is spared. In contrast, resveratrol reduces release of neurocan and brevican, extracellular matrix components that restrict neuroplasticity, from both neurons and glia. These data underscore the diversity of resveratrol's actions with respect to affected cell types and molecular targets and also suggest that further studies may be warranted to determine if its effects on glial MMP release could make it a useful adjunct for AD‐ and/or anti‐amyloid therapy‐related damage to the blood brain barrier. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ResveratrolMatrix Metalloproteinase 9NeuronsNeurogliaAlzheimer DiseaseHumansAnimalsMaleFemaleAgedCells, CulturedStilbenesAged, 80 and overApolipoprotein E4Middle Aged

Stichwörter der Autor:innen

MMP ECMPNN resveratrol neuron glia

Substanzen

ResveratrolMatrix Metalloproteinase 9StilbenesApolipoprotein E4

Autor:innen und Institutionen

  • Department of Neuroscience, Georgetown University Medical Center, Washington, District of Columbia, USA.
  • Interdisciplinary Program in Neuroscience, Georgetown University, Washington, District of Columbia, USA.
  • Department of Pharmacology and Physiology, Georgetown University Medical Center, Washington, District of Columbia, USA.
  • Department of Biology, Georgetown University, Washington, District of Columbia, USA.
  • Department of Neurology, Georgetown University Medical Center, Washington, District of Columbia, USA.

ORCID-Profile: Katherine Conant

Förderung

  • NIH HHS
  • NIA NIH HHS
  • National Institutes of Health

Zitieren

APA

Amontree, M., Nelson, M., Stefansson, L., Pak, D., Maguire-Zeiss, K., Turner, R. S., & Conant, K. (2024). Resveratrol differentially affects MMP‐9 release from neurons and glia; implications for therapeutic efficacy. Journal of Neurochemistry, 168(9), 1895-1908. https://doi.org/10.1111/jnc.16031

Vancouver

Amontree M, Nelson M, Stefansson L, Pak D, Maguire-Zeiss K, Turner RS, et al. Resveratrol differentially affects MMP‐9 release from neurons and glia; implications for therapeutic efficacy. Journal of Neurochemistry. 2024;168(9):1895-1908. doi:10.1111/jnc.16031

BibTeX
@article{Amontree2024,
  author = {Amontree, Matthew and Nelson, Matthew and Stefansson, Lara and Pak, Daniel and Maguire-Zeiss, Kathleen and Turner, R Scott and Conant, Katherine},
  title = {Resveratrol differentially affects MMP‐9 release from neurons and glia; implications for therapeutic efficacy},
  journal = {Journal of Neurochemistry},
  year = {2024},
  volume = {168},
  number = {9},
  pages = {1895--1908},
  doi = {10.1111/jnc.16031}
}
Kostenlos starten →